Is there an Indian generic version of Cabozantinib?
Cabozantinib (Cabozantinib) is an oral multi-target tyrosine kinase inhibitor, also known as a targeted therapy drug. It exerts anti-tumor effects by inhibiting the activity of multiple receptor kinases and interfering with the proliferation, angiogenesis and metastasis of tumor cells.
There are no generic cabozantinib drugs officially launched in India, mainly from Bangladesh and Laos. Cabozantinib is not currently on the market in China, and therefore is not included in medical insurance, because it requires approval from the National Medical Products Administration. Therefore, patients cannot purchase it domestically and need to purchase it through overseas channels. There are original and generic cabozantinib drugs abroad. The original drugs are mainly Japanese original drugs, Turkish original drugs and European version original drugs. The price is relatively high, ranging from 35,000 to 46,000 yuan. Foreign generic drugs are mainly Lao generic drugs and Bangladeshi generic drugs, with prices ranging from 1,300 to 2,700 yuan. The price is much cheaper than original drugs and is more suitable for the needs of patients in ordinary families. The ingredients of original drugs and generic drugs are basically the same.
The use of cabozantinib may cause a series of side effects, including but not limited to hypertension, diarrhea, fatigue, hand-foot syndrome, nausea, loss of appetite, etc. Therefore, patients should pay close attention to their symptoms and undergo regular medical monitoring when using the drug.
Cabozantinib is a targeted therapy drug that shows certain therapeutic effects on certain cancer types, such as renal cell carcinoma, thyroid cancer and hepatocellular carcinoma, by inhibiting the activity of multiple receptor kinases. However, the drug should be used according to the doctor's prescription and advice, and the patient's condition and adverse reactions should be closely monitored. If you or someone you know needs to use cabozantinib, it is recommended to consult a professional doctor as soon as possible to obtain the most appropriate treatment plan.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)